EUnetHTA Joint Action 3 (2016-2021)

Home  /  EUnetHTA Joint Action 3 (2016-2021)

This is the pharmaceutical Joint Assessment PTJA09 on brolucizumab. In February 2020, the European Commission granted marketing authorisation for Beovu® (brolucizumab) for the treatment of adults with neovascular (wet) AMD. This Joint Assessment aims to compare the clinical effectiveness and

The aim of this guidance document is to pass on some knowledge and know-how to all stakeholders with an interest in economic evaluations by providing an overview of important points for consideration when performing/assessing such evaluations, supported by a selection

The final project plan of the relative effectiveness assessment of ‘cefiderocol for the treatment of infections due to aerobic Gram-negative bacteria in adult patients with limited treatment options’ is now available for access. The final assessment report will be published

On 6 Dec 2019, Celgene officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for enasidenib. Since no CHMP opinion will be granted at this stage, EUnetHTA